Skip to Content
Merck
CN

EHU142801

MISSION® esiRNA

targeting human TCN1

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

NACRES:
NA.51
UNSPSC Code:
41105324

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

description

Powered by Eupheria Biotech

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

TCTCAAGGAGCATTCAGCAATCCAAACGCTGCAGCCCAGGTCTTACCTGCCCTGATGGGAAAGACCTTCTTGGATATTAACAAAGACTCTTCTTGCGTCTCTGCTTCAGGTAACTTCAACATCTCCGCTGATGAGCCTATAACTGTGACACCTCCTGACTCACAATCATATATCTCCGTCAATTACTCTGTGAGAATCAATGAAACATATTTCACCAATGTCACTGTGCTAAATGGTTCTGTCTTCCTCAGTGTGATGGAGAAAGCCCAGAAAATGAATGATACTATATTTGGTTTCACAATGGAGGAGCGCTCATGGGGGCCCTATATCACCTGTATTCAGGGCCTATGTGCCAACAATAATGACAGAACCTACTGGGAACTTCTGAGTGGAGGCGAACCACTGAGCCAAGGAGCTGGTA

Ensembl | human accession no.

ENSG00000134827

NCBI accession no.

NM_001062

shipped in

ambient

storage temp.

−20°C

Quality Level

100

General description

MISSION esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
QCS
DOR

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ying Wang et al.
OncoTargets and therapy, 11, 4253-4261 (2018-08-14)
Hypopharyngeal squamous cell carcinoma (HPSCC) is an aggressive head and neck squamous cell carcinoma with poor prognosis. Neoadjuvant chemotherapy (NACT) followed by concurrent chemoradiotherapy could provide better efficacy in HPSCC treatment. Identification of predictive biomarkers is critically needed to improve
Begoña Ugarte-Uribe et al.
Bioorganic & medicinal chemistry, 25(1), 175-186 (2016-11-05)
The ability of oligonucleotides to silence specific genes or inhibit the biological activity of specific proteins has generated great interest in their use as research tools and therapeutic agents. Unfortunately, their biological applications meet the limitation of their poor cellular

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service